Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Ultragenyx Pharmaceutical Inc. - Common Stock
(NQ:
RARE
)
23.27
-0.12 (-0.51%)
Streaming Delayed Price
Updated: 2:08 PM EDT, May 26, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
554,328
Open
23.62
Bid (Size)
23.25 (100)
Ask (Size)
23.28 (300)
Prev. Close
23.39
Today's Range
23.01 - 23.75
52wk Range
18.29 - 42.37
Shares Outstanding
70,814,462
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 22, 2026
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx to Participate at Bank of America’s 2026 Healthcare Conference
May 06, 2026
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Performance
YTD
-1.4%
-1.4%
1 Month
-3.0%
-3.0%
3 Month
+3.4%
+3.4%
6 Month
-29.0%
-29.0%
1 Year
-33.7%
-33.7%
More News
Read More
Ultragenyx Pharma (NASDAQ:RARE) Dips After Q1 Miss as Pipeline Catalysts Loom
↗
May 05, 2026
Via
Chartmill
Ultragenyx Reports First Quarter 2026 Financial Results and Corporate Update
May 05, 2026
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx to Host Conference Call for First Quarter 2026 Financial Results and Corporate Update
April 29, 2026
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
April 24, 2026
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
ULTRAGENYX URGENT DEADLINE: Bragar Eagel & Squire, P.C. Reminds Ultragenyx (NASDAQ:RARE) Investors of the April 6th Lead Plaintiff Deadline and Urges Investors to Contact the Firm
April 06, 2026
From
Bragar Eagel & Squire
Via
GlobeNewswire
RARE FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026
April 06, 2026
From
Faruqi & Faruqi, LLP
Via
Business Wire
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm
April 06, 2026
From
Schall Law
Via
GlobeNewswire
Ultragenyx 72 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc. - RARE
April 03, 2026
From
Kahn Swick & Foti, LLC
Via
Business Wire
RARE Deadline: Rosen Law Firm Urges Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
April 03, 2026
From
The Rosen Law Firm, P.A.
Via
Business Wire
ULTRAGENYX DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure Counsel Before Important April 6 Deadline in Securities Class Action – RARE
April 02, 2026
From
The Rosen Law Firm PA
Via
GlobeNewswire
RARE SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026
April 02, 2026
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
Ultragenyx Vaults Toward Commercialization as FDA Accepts Landmark Gene Therapy BLA
April 02, 2026
Via
MarketMinute
Topics
Intellectual Property
Lawsuit
Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc. - RARE
April 02, 2026
From
SkyMedia, LLC
Via
GlobeNewswire
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm
April 02, 2026
From
Schall Law
Via
GlobeNewswire
Ultragenyx Announces U.S. FDA Acceptance of BLA Resubmission for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)
April 02, 2026
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
ULTRAGENYX PHARMACEUTICAL INC. (NASDAQ: RARE) CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Investors to Inquire About a Securities Fraud Class Action by April 6, 2026
April 01, 2026
From
Berger Montague
Via
GlobeNewswire
Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
March 31, 2026
From
Kahn Swick & Foti, LLC
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming Deadlines – RARE
March 31, 2026
From
Pomerantz LLP
Via
GlobeNewswire
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm
March 30, 2026
From
Schall Law
Via
GlobeNewswire
Ultragenyx Announces FDA Clearance of Investigational New Drug (IND) Application for UX016, a Sialic Acid Prodrug for the Treatment of GNE Myopathy
March 30, 2026
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc. - RARE
March 25, 2026
From
SkyMedia, LLC
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Ultragenyx (NASDAQ: RARE) Investors of the Upcoming April 6th Lead Plaintiff Deadline and Urges Investors to Contact the Firm
March 25, 2026
From
Bragar Eagel & Squire
Via
GlobeNewswire
RARE Investor Alert: Ultragenyx Pharmaceutical Inc. Stockholders with Large Losses Should Contact Robbins LLP for Information About the Securities Fraud Class Action Lawsuit
March 25, 2026
From
Robbins LLP
Via
Business Wire
Frequently Asked Questions
Is Ultragenyx Pharmaceutical Inc. - Common Stock publicly traded?
Yes, Ultragenyx Pharmaceutical Inc. - Common Stock is publicly traded.
What exchange does Ultragenyx Pharmaceutical Inc. - Common Stock trade on?
Ultragenyx Pharmaceutical Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Ultragenyx Pharmaceutical Inc. - Common Stock?
The ticker symbol for Ultragenyx Pharmaceutical Inc. - Common Stock is RARE on the Nasdaq Stock Market
What is the current price of Ultragenyx Pharmaceutical Inc. - Common Stock?
The current price of Ultragenyx Pharmaceutical Inc. - Common Stock is 23.27
When was Ultragenyx Pharmaceutical Inc. - Common Stock last traded?
The last trade of Ultragenyx Pharmaceutical Inc. - Common Stock was at 05/26/26 02:08 PM ET
What is the market capitalization of Ultragenyx Pharmaceutical Inc. - Common Stock?
The market capitalization of Ultragenyx Pharmaceutical Inc. - Common Stock is 1.65B
How many shares of Ultragenyx Pharmaceutical Inc. - Common Stock are outstanding?
Ultragenyx Pharmaceutical Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
